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Silencing Innovation: The Patent Eligibility of
siRNA Therapeutics
Alexander M. Walker, PhD
Small interfering ribonucleic acids (siRNAs) are a type of
nucleic acid capable of initiating the ribonucleic acid interference (RNAi) pathway.1 siRNA-induced RNAi creates a gene-silencing effect that can be used to affect the function of difficultto-treat diseases and may be especially useful for the treatment
of certain cancers.2 The silencing effect is created by complementary recognition of the siRNA sequence and the messenger RNA
sequence (mRNA) of the target gene.3 Several siRNA-based therapeutics have received approval from the U.S. Food and Drug
Administration (FDA) to begin clinical trials and one siRNA
therapeutic has recently received FDA marketing authorization.4
Whether an invention represents a subject matter eligible
for patenting is determined by 35 U.S.C. § 101,5 which also lists

1. RNA Interference (RNAi), NAT’L CENTER FOR BIOTECH. INFO.,
https://www.ncbi.nlm.nih.gov/probe/docs/techrnai/ (last visited Oct. 27, 2018).
2. See Sherry Y. Wu et al., Targeting the Undruggable: Advances and Obstacles in Current RNAi Therapy, SCI. TRANSLATIONAL MED., June 2014, at 1,
1 (“[An siRNA] approach has attracted particular interest within oncology,
where many important targets have proven undruggable.”).
3. See Ashley J. Pratt & Ian J. MacRae, The RNA-Induced Silencing Complex: A Versatile Gene-Silencing Machine, 284 J. BIOLOGICAL CHEMISTRY 17897,
at 17899 (2009) (“[T]he [siRNA] guide strand form[s] a Watson-Crick-paired, Aform double helix with a complementary region of the target RNA.”); see also
discussion of complementary binding infra Section I.A.
4. See Chiranjib Chakraborty et al., Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine, 8 MOLECULAR THERAPY
NUCLEIC ACIDS 132, 132 (2017); FDA Approves First-Of-Its Kind Targeted RNABased Therapy to Treat a Rare Disease, U.S. FOOD & DRUG ADMIN. (Aug. 10,
2018),
https://www.fda.gov/news-events/press-announcements/fda-approvesfirst-its-kind-targeted-rna-based-therapy-treat-rare-disease [hereinafter RNABased Therapy] (“To date, approximately 20 clinical trials have been initiated
using miRNA- and siRNA-based therapeutics.”).
5. See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569
U.S. 576, 595 (2013).
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the statutory categories available to patentees.6 Patent eligibility has traditionally foreclosed certain subject matter called “judicial exceptions,”7 which includes laws of nature, natural phenomena, and abstract ideas.8 The patenting of deoxyribonucleic
acids (DNA) began in force following the Supreme Court’s decision in Diamond v. Chakrabarty.9 Following this decision, DNA
sequences (including genomic DNA) were routinely patented 10
until key court rulings held many types of DNA patents ineligible for patenting.11 However, no case law has directly addressed
the patent eligibility of DNA or ribonucleic acid (RNA) therapeutics.12
The goal of this note is to explore the patent eligibility of
siRNA therapeutics. Part I of this note discusses the molecular
mechanism of siRNA, the judicial exceptions to 35 U.S.C. § 101,
relevant case law on the patent eligibility of DNA molecules, and
the general economic effects of patent protection. Though there
is no case law directly addressing the patent eligibility of RNA
molecules, applying holdings on DNA molecules to siRNA suggests that it has limited patent eligibility, potentially only as
part of a “method of treatment” claim,13 as discussed in Part II

6. 35 U.S.C. § 101 (1952).
7. CLS Bank Int’l v. Alice Corp. Pty. Ltd., 717 F.3d 1269, 1277 (Fed. Cir.
2013), aff’d, 573 U.S. 208 (2014) (“If the invention falls within one of the statutory categories, we must then determine whether any of the three judicial exceptions nonetheless bars such a claim.”).
8. Diamond v. Diehr, 450 U.S. 175, 185 (1981).
9. See Aaron S. Kesselheim, Gene Patenting—The Supreme Court Finally
Speaks, 369 NEW ENG. J. MED. 869, 871 (2013) (Discussing “[t]he landmark
1980 case of Diamond v. Chakrabarty, which ushered in the modern explosion
in biotechnology patents.”).
10. See, e.g., Vincent Y. Ling, Patently Ours? Constitutional Challenges to
DNA Patents, 14 U. PA. J. CONST. L. 813, 813 (2012) (“Since [1980], the PTO has
granted over 40,000 patents on DNA.”).
11. See, e.g., Myriad, 569 U.S. at 577.
12. See Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1373 n.6
(Fed. Cir. 2018) (“We express no opinion on subject matter eligibility of method
claims that exploit DNA or RNA for drug-like new applications.”); see also Robert W. Esmond & Alex Kwan-Ho Chung, The Patent Landscape of siRNA Nanoparticle Delivery, 11 NANOTECH. L. & BUS. 15, 26–27 (2014) (describing litigation of siRNA as dealing with inventorship, patent malpractice, and trade secret
disputes).
13. See, e.g., Vanda Pharm. Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d
1117, 1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (U.S. Jan.
17, 2019) (No. 18-817).
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of this note. However, siRNA represents a significant area of potential biopharmaceutical investment14 and offers numerous
medical advantages over conventional therapeutics.15 Therefore,
Part III of this note offers an alternative interpretation of DNA
case law that could expand the statutory categories available to
potential siRNA patents as well as a legislative solution capable
of offering non-patent market exclusivity.
I.

BACKGROUND

Part I of this note will begin by giving a brief primer on the
scientific principles underlying siRNA before transitioning into
an overview of patentable subject matter. It will then explore
case law interpreting 35 U.S.C. § 101 with a focus on holdings
related to nucleotide technologies.16 Further, this section will
provide context on the patent landscape of siRNA therapeutics
and the forecasted economy of siRNA technologies.
A. A BRIEF PRIMER ON NUCLEOTIDES
Structurally, DNA generally possesses four types of nucleotide bases: adenine, thymine, guanine, and cytosine.17 RNA, a
closely related biological macromolecule, contains uracil in lieu
of thymine, but otherwise shares the same bases as DNA.18 The
sequence of nucleotide bases possessed by a given DNA or RNA
molecule is generally referred to as its “sequence.”19 Further, nucleotides have directionality imparted by the presence of a phosphate group at one end (referred to as the 5’ end) and a free hydroxyl group at the other (referred to as the 3’ end) of each
14. Chakraborty et al., supra note 4, at 134 (“[B]iopharma companies are
investing in the development of miRNA- and siRNA-based therapeutic molecules. However, there is a challenge for small biotechnology companies because
there is some financial volatility in this area.”).
15. Cf. Novartis and UC Berkeley Take on “Undruggable” Proteins in New
Collaboration, NOVARTIS: STORIES (Sept. 28, 2017), https://www.novartis.com/stories/discovery/novartis-and-uc-berkeley-take-undruggable-proteinsnew-collaboration (Explaining that most proteins, and thus most disease targets, are undruggable) [hereinafter Novartis] (internal quotation marks omitted).
16. See, e.g., Myriad, 569 U.S. at 594–95 (holding that cDNA is patent-eligible subject matter and that genomic DNA is not).
17. E.g., DNA and RNA, JEFFERSON, https://cm.jefferson.edu/learn/dnaand-rna/ (last visited Feb. 13, 2019).
18. E.g., id.
19. E.g., id. (“It is the sequence of these four bases along the backbone that
encodes information.”).
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nucleic acid molecule.20 Because longer nucleotide strands are
polymers formed of repeating nucleotide units, they also have 5’
and 3’ ends.21
DNA is generally double-stranded, while RNA is often (but
not always) single-stranded.22 Two DNA or RNA strands interact with one another through hydrogen bonds formed between
their respective bases. Double-stranded DNA or RNA molecules
generally have an anti-parallel structure, wherein the individual
strands run parallel but in opposite directions.23 The process by
which two nucleotide bases bond is generally referred to as “complementary base-pairing.”24 Moreover, base-pairing tends to occur in a predictable regime—adenine base-pairs with thymine
(or uracil, in the case of RNA) and guanine base-pairs with cytosine.25 When all of the bases of two DNA or RNA strands are able
to base-pair, those two sequences are also said to be “complementary” or “fully complementary.”26 Strands that are not fully complementary but still have some bases engaging in complementary base-pairing are said to be “partially” complementary.27
Notably, not all of the DNA within a given genome codes for
a protein or another functional gene product.28 Following RNA
transcription, in which an RNA strand is synthesized from a
template DNA strand, a process called “RNA splicing” removes

20. E.g.,
DNA,
UNI.
OF
QUEENSL.:
DIAMANTINA
INST.,
https://di.uq.edu.au/community-and-alumni/sparq-ed/sparq-ed-services/dna
(last visited Feb. 13, 2019).
21. See id.
22. See DNA and RNA, supra note 17.
23. E.g., id.
24. E.g., id.
25. E.g., id.
26. See, e.g., id.; see also, e.g., Akira Shimizu et al., Characterisation of Cytoplasmic DNA Complementary to Non-Retroviral RNA Viruses in Human Cells,
NATURE SCI. REP., May 30, 2014, at 1, 2 (describing an RNA-DNA binding interaction as “fully complementary”).
27. See, e.g., Susanna Monti et al., Complementary and Partially Complementary DNA Duplexes Tethered to a Functionalized Substrate: A Molecular
Dynamics Approach to Biosensing, 13 PHYSICAL CHEMISTRY CHEM. PHYSICS
12479, 12478 (2011) (describing mismatched DNA sequences as “partially complementary”).
28. See, e.g., Transcription, Translation and Replication, ATDBIO,
https://www.atdbio.com/content/14/Transcription Translation-and-Replication
(last visited Feb. 13, 2019).
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the noncoding regions, called “introns,” from the coding regions,
called “exons.”29
B. THE TECHNOLOGY ITSELF: HOW DOES SIRNA WORK?
Though RNAs are perhaps best known by the role that
mRNA30 plays in gene expression as an intermediary between
DNA and protein,31 other forms of RNA molecules have a wide
range of functional and regulatory roles.32 RNA interference
(RNAi) is a natural mechanism of regulating gene expression
that utilizes small RNA sequences33 and may have an “important role in pathogen resistance.”34 Generally, the process of
using RNAi to affect gene expression is known as “silencing.”35
The RNAi pathway is sensitive to “trigger RNA” molecules, most
commonly either pri-microRNA (pri-miRNA)36 or doublestranded RNA (dsRNA).37 The pre-miRNAs are expressed naturally in mammalian cells, typically have a short-hairpin structure, and are processed by the cell into pre-miRNA that is then
processed into miRNA.38 Unlike pre-miRNA, dsRNA precursors

29. See, e.g., id.
30. See, e.g., What is RNA?, THE RNA SOC’Y, https://www.rnasociety.org/about/ (last visited Nov. 18, 2018) (“A central tenet of molecular biology states that the flow of genetic information in a cell is from DNA through
RNA to proteins . . . .”).
31. See, e.g., Gene Expression, NAT’L CANCER INST.: DICTIONARY OF CANCER
TERMS,
https://www.cancer.gov/publications/dictionaries/cancerterms/def/gene-expression (last visited Nov. 27, 2018) (Defining “gene expression” as “[t]he process by which a gene gets turned on in a cell to make RNA
and proteins.”),
32. See, e.g., THE RNA SOCIETY, supra note 30 (“In recent years, however,
we have begun to realize that the roles adopted by RNA are much broader and
much more interesting.”).
33. RNA Interference (RNAi), supra note 1.
34. Id.
35. Id.
36. See generally Louise Adams, Pri-miRNA Processing: Structure Is Key,
18 NATURE REVS. GENETICS 145, 145 (2017) (explaining that pri-miRNA is processed into pre-miRNA, which is transported and processed into mature
miRNA); see also generally Lin He and Gregory J. Hannon, microRNAs: Small
RNAs with a Big Role in Gene Regulation, 5 NATURE REVS. GENETICS 522, 524–
25 (2004) (explaining the biogenesis of miRNA).
37. See RNA Interference (RNAi), supra note 1.
38. See, e.g., Precursor miRNAs for Successful miRNA Functional Studies,
THERMOFISHER SCI., https://www.thermofisher.com/us/en/home/references/ambion-tech-support/microrna-studies/tech-notes/precursor-mirnas-for-successful-mirna-functional-studies.html (last visited Jan. 23, 2019).
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can be derived from endogenous or exogenous39 sources and are
processed by the cell into siRNAs.40
Once processed, miRNA and siRNA are loaded into Argonaute (Ago) proteins to form an RNA-induced silencing complex
(RISC)41 capable of targeting one or more mRNA sequences for
silencing.42 The sequence of the miRNA or siRNA controls which
mRNA is recognized as the target mRNA through complementary interaction.43 Once the RISC complex has bound the target
sequence, it performs its gene-silencing function through one of
four major mechanisms: by “slicing” or chemically breaking the
target RNA, by preventing translation of it into a protein (either
by blocking access to the target RNA or by targeting the RNA for
degradation by other enzymes), by modifying the histones associated with the locus of the gene encoding the RNA target and
thereby altering the rate at which the gene is transcribed, or by
eliminating the DNA encoding the RNA from the genome altogether.44
There are a number of important differences between
miRNA and siRNA molecules beyond their structural dissimilarity.45 An miRNA can bind to sequences with which it is only partially complementary, allowing it to target a broad range of sequences.46 Conversely, an siRNA must be “fully complementary

39. “Endogenous” refers to molecules “[a]rising within the organism or
cell.” E.g., Endogenous, GENSCRIPT: MOLECULAR BIOLOGY GLOSSARY,
https://www.genscript.com/molecular-biology-glossary/935/endogenous
(last
visited Feb. 13, 2019). “Exogenous” refers to molecules “[a]rising from a source
outside the organism or cell.” E.g., Exogenous, GENSCRIPT: MOLECULAR BIOLOGY GLOSSARY, https://www.genscript.com/molecular-biology-glossary/1013/exogenous (last visited Feb. 13, 2019).
40. Pratt & MacRae, supra note 3 at 17898 (“Silencing RNA can be derived
from exogenous or intracellular origins . . . .”).
41. See RNA Interference (RNAi), supra note 1.
42. See Pratt & MacRae, supra note 3, at 17899 (“The core architecture of
Argonaute and guide RNA allows RISC to efficiently locate specific targets
within the vast pool of cellular RNAs.”).
43. Id. (“[T]he [miRNA or siRNA] guide strand form[s] a Watson-Crickpaired, A-form double helix with a complementary region of the target RNA.”).
44. See id. at 17989–90.
45. Even among experts in the field, these differences are sometimes unnoticed because “the distinction [between miRNA and siRNA] has been obscured
because they are associated with common enzymes . . . and their functions overlap with each other to a certain extent.” Jenny K.W. Lam et al., siRNA Versus
miRNA as Therapeutics for Gene Silencing, 4 MOLECULAR THERAPY NUCLEIC
ACIDS 252, 253 (2015).
46. Id. at 254–55.
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to its target mRNA,” thereby making siRNA-based RNAi highly
specific.47 Moreover, introducing synthetic siRNA directly to
mammalian cells (rather than the longer dsRNA precursors) has
been shown to further increase the specificity of the resulting
RNAi response.48 Because siRNA is fully complementary to its
target sequence, it also is able to activate the “slicing” function
of the siRNA-RISC complex.49 Conversely, miRNA-mediated silencing usually “occurs through translation repression, or degradation by deadenylation, decapping or exonuclease action.”50 At
least for these reasons, siRNAs have been favored over miRNA
for therapeutic applications of RNAi-based gene silencing.51
Further, siRNA-mediated RNAi offers a major improvement
to conventional therapeutics, especially in the treatment of certain cancers.52 This is in part due to the ability of siRNA to target
any given mRNA sequence and only that sequence.53 Moreover,
siRNA technologies have the capability to affect the expression
(and thereby the function) of a broad range of genes as compared
to traditional small molecule drugs—conventional therapeutics
can only target certain classes of proteins, leaving “some diseases untreatable.”54 By contrast, siRNAs “can downregulate the
expression of virtually all genes and their mRNA transcripts,”
significantly broadening the range of treatable targets “[s]ince

47. Id. at 253.
48. See id. (“[D]irect introduction of synthetic siRNAs, instead of the long
dsRNAs (thus skipping the step of Dicer processing), leads to effective RNAi
without the complication of activating the IFN response.”).
49. See id. at 253–55 (“[T]he guide strand guides the active RISC to its target mRNA for cleavage by AGO2. As the guide strand only binds to mRNA that
is fully complementary to it, siRNA causes specific gene silencing.”).
50. Id. at 255.
51. See id. at 255–56, 264 (describing siRNAs as “extremely useful for targeting single gene disorders” and as having been favored by researchers as potential therapeutics due to the uncertainty surrounding miRNA “mechanism of
action and specificity”).
52. See, e.g., Kevin Bullis, Gene-Silencing Drugs Finally Show Promise,
MIT
TECH.
REV.
(Sep.
14,
2014),
https://www.technologyreview.com/s/530631/gene-silencing-drugs-finally-show-promise/ (“Treating
cancer is one area where RNAi’s particular advantages are expected to shine.”).
53. See id. (“RNAi can be extremely precise, potentially shutting down only
proteins found in cancer cells.”).
54. Novartis, supra note 15 (internal quotation marks omitted) (quoting
Dan Nomura, director of the Novartis-Berkeley Center for Proteomics and
Chemistry Technologies).
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many diseases result from the expression of undesired or mutated genes, or from overexpression of certain normal genes.”55
Despite the relative advantages of siRNA therapeutics, delivery
of siRNA into the cell remains a major challenge.56
Conventional siRNA therapeutics contain roughly nineteen
to twenty-one nucleotides identical in sequence to the target
gene as well as “two nucleotide overhangs at the 3’ end . . . which
are important for recognition by the RNAi machinery.”57 However, at least one study has shown that dsRNAs up to twentyseven nucleotides in length are significantly “more potent inducers of RNAi than conventional siRNAs.”58 Using dsRNAs with
thirty or more nucleotides is thought to be undesirable because
those dsRNAs can “activate[] . . . the interferon pathway,”59 an
immune system response to pathogen infection.60
C. THE JUDICIAL EXCEPTIONS TO 35 U.S.C § 101 LIMIT PATENT
ELIGIBILITY
Section 101 of the Patent Act establishes the four statutory
categories of patentable subject matter: processes, machines, articles of manufacture, and compositions of matter. 61 However,
merely reciting subject matter directed to one of the four statutory categories does not guarantee patent eligibility.62 Rather,
“laws of nature, natural phenomena, and abstract ideas” are

55. Lam et al., supra note 45, at 255.
56. Hassan Dana et al., Molecular Mechanisms and Biological Functions of
siRNA, INT. J. BIOMED. SCI., June 2017, at 48, 50 (“The fantastic potential of
siRNA to silence important genes in disease pathways comes with noteworthy
challenges and barriers in its delivery.”).
57. Lam et al., supra note 45, at 255 (citing S. Patrick Walton et al., Designing Highly Active siRNAs for Therapeutic Applications, 277 FEBS J. 4806,
4807 (2010)).
58. Dong-Ho Kim et al., Synthetic dsRNA Dicer Substrates Enhance RNAi
Potency and Efficacy, 23 NATURE BIOTECH. 222, 225 (2005).
59. Id. at 222.
60. See generally Interferon (IFN) Cell Signaling Pathway, THERMOFISHER,
https://www.thermofisher.com/us/en/home/life-science/cell-analysis/signaling-pathways/interferon/interferon-overview.html (last visited Mar. 5,
2019) (“The interferon . . . pathway plays a critical role in the human immune
response.”).
61. See 35 U.S.C. § 101 (1952) (listing, in general terms, subject matter eligible for patent).
62. See generally U.S. PAT. & TRADEMARK OFF., MPEP § 2104 (9th ed., Rev.
8, Jan. 2018) (describing four requirements, in addition to inclusion in one of
these four statutory categories, for a patent application to be valid).

2020]

SILENCING INNOVATION

341

generally not patentable.63 These exceptions to are often referred
to as “judicial exceptions” to § 101’s broad statutory categories 64
and are designated as such because they are rooted in the common law rather than the statutory language of 35 U.S.C. § 101.65
The judicial exceptions were developed to prevent the patenting
of “basic tools of scientific and technological work”66 and concepts
that are “part of the storehouse of knowledge of all men . . . free
to all men and reserved exclusively to none.”67 From a policy perspective, the judicial exceptions are targeted to prevent patents
from “reach[ing] too far and claim[ing] too much, on balance obstructing rather than catalyzing innovation.”68 Thus, patents
that simply recite “an instruction to ‘apply the natural law’ . . .
foreclose[] more future invention than the underlying discovery
could reasonably justify.”69 However, courts have recognized
that interpreting the judicial exceptions too broadly could seriously undermine the purpose of patent law because “all inventions at some level embody, use, reflect, rest upon, or apply laws
of nature, natural phenomena, or abstract ideas.”70
In order to balance these competing policy interests, the Supreme Court has provided a two-step framework, articulated in
Alice Corp. v. CLS Bank International, to determine if a claim
that recites subject matter directed to one of the judicial exceptions is nonetheless eligible for patenting.71 If a court determines

63. Diamond v. Diehr, 450 U.S. 175, 185 (1981) (“Excluded from . . . patent
protection are laws of nature, natural phenomena, and abstract ideas.”).
64. CLS Bank Int’l v. Alice Corp. Pty. Ltd., 717 F.3d 1269, 1277 (Fed. Cir.
2013), aff’d, 573 U.S. 208 (2014) (“If the invention falls within one of the statutory categories, we must then determine whether any of the three judicial exceptions nonetheless bars such a claim.”); U.S. PAT. & TRADEMARK OFF., supra
note 62 (“[A] claimed invention must be directed to patent-eligible subject matter and not a judicial exception . . . .”).
65. Bilski v. Kappos, 561 U.S. 593, 601 (2010) (citing Diamond v.
Chakrabarty, 447 U.S. 303, 309 (1980)) (“The Court’s precedents provide three
specific exceptions to § 101’s broad patent-eligibility principles: ‘laws of nature,
physical phenomena, and abstract ideas.’”) (emphasis added).
66. Gottschalk v. Benson, 409 U.S. 63, 67 (1972).
67. Bilski, 561 U.S. at 602 (quoting Funk Bros. Seed Co. v. Kalo Inoculant
Co., 333 U.S. 127, 130 (1948)) (internal quotation marks omitted).
68. CLS Bank, 717 F.3d at 1277.
69. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 86
(2012).
70. Id. at 71.
71. See Alice Corp. Pty. v. CLS Bank Int’l, 573 U.S. 208, 216 (2014) (quoting
Mayo, 566 U.S. at 84) (“First, we determine whether the claims at issue are
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that a particular claim or set of claims are directed to one of the
judicial exceptions, it must examine the elements of the claim to
determine if there are “additional elements that ‘transform the
nature of the claim’ into a patent-eligible application.”72 An additional element or a combination of additional elements
amounting to “well-understood, routine, conventional activity,”
as recognized by a court or a person of ordinary skill in the art,
is not sufficient to transform a claim directed to a judicial exception into patent-eligible subject matter.73 Further, claim elements are considered as a whole, meaning that even where individual steps may be well understood, routine, or conventional,
the combination may “‘transform the nature of the claim’ into a
patent-eligible application.”74 If the additional element or combination of elements “amounts to significantly more than a patent upon the [judicial exception] itself,” then the claim is eligible for patenting.75
Therapeutics and therapeutic strategies have posed special
problems for courts interpreting 35 U.S.C. § 101. Methods of diagnosis have generally been regarded by both the Supreme
Court and the Federal Circuit as reciting patent-ineligible subject matter insofar as such methods often are difficult to distinguish from the natural law they are applying.76 However, the
Federal Circuit recently held that a method of treating schizophrenia using the anti-psychotic drug iloperidone was patent-

directed to one of those patent-ineligible concepts. If so, we then ask, ‘What else
is there in the claims before us?’”).
72. Id. at 216.
73. Mayo, 566 U.S. at 68 (citing Parker v. Flook, 437 U.S. 584, 590 (1978))
(“[Well-understood, routine, or conventional] activity is normally not sufficient
to transform an unpatentable law of nature into a patent-eligible application of
such a law.”).
74. Alice, 573 U.S. at 211 (quoting Mayo, 566 U.S. at 74); see also Rapid
Litig. Mgmt. Ltd. v. CellzDirect, Inc., 827 F.3d 1042, 1051 (Fed. Cir. 2016) (quoting Diamond v. Diehr, 450 U.S. 175, 188 (1981)) (“[A] new combination of steps
in a process may be patentable even though all the constituents of the combination were well known and in common use before the combination was made.”)
(internal quotation marks omitted).
75. Mayo, 566 U.S. at 73.
76. E.g., Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1377
(Fed. Cir. 2015) (holding a method of diagnosis based on “detecting” amplified
DNA as patent ineligible on the grounds that the method used conventional
steps to apply a natural law).

2020]

SILENCING INNOVATION

343

eligible.77 Because the method at issue recited “using a specific
compound at specific doses to achieve a specific outcome,” it was
found to contain “more than the natural relationship” between
iloperidone and schizophrenia.78
D. THE MYRIAD GENETICS SAGA: DEFINING PATENT ELIGIBILITY
OF NUCLEOTIDES
Nucleotide technologies present a difficult case for patent
eligibility because of the close relationship between biotechnology and the natural properties of DNA.79 The Supreme Court
ruled on the patent eligibility of nucleotide sequences generally
in Association for Molecular Pathology v. Myriad Genetics.80
Myriad determined the chromosomal coordinates for the BRCA1
and BRCA2, which are commonly implicated in breast and ovarian cancer.81 At issue in Myriad were nine claims from three patents, though the holding focused in particular on four claims
directed to different DNA formulations: the full-length BRCA1
gene sequence, the BRCA1 complementary DNA (cDNA) sequence,82 any DNA molecule of at least fifteen nucleotides having the identical sequence to any portion of the full-length
BRCA1 sequence, and any DNA molecule of at least fifteen nucleotides having the identical sequence to any portion of the
BRCA1 cDNA sequence.83 In effect, Myriad’s patents gave it “the
exclusive right to isolate and individual’s BRCA1 and BRCA2
genes (or any strand of 15 or more nucleotides within the genes)

77. Vanda Pharm. Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 1117, 1121,
1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (U.S. Jan. 17,
2019) (No. 18-817).
78. Id.
79. Cf. Diane Gershon, Recombinant DNA Technology, 348 NATURE 92, 92–
93 (1990) (describing the commercialization of recombinant DNA technology,
which exploits natural properties of DNA, including hybridization, polymerization, mRNA structure, and restriction enzyme-based DNA modification).
80. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576,
580 (2013) (“This case . . . requires us to resolve whether a naturally occurring
segment of deoxyribonucleic acid (DNA) is patent eligible under 35 U.S.C. § 101
by virtue of its isolation from the rest of the human genome.”).
81. See id. at 582–83 (“Mutations in these genes can dramatically increase
an individual’s risk of developing breast and ovarian cancer.”).
82. A “cDNA” molecule is created by using an mRNA molecule as a template to synthesize DNA “complementary” in sequence to the mRNA molecule.
See id. at 582 (describing a laboratory method by which DNA can be created
synthetically from “an mRNA molecule”).
83. See id. at 584 (describing each claim at issue).

344

MINN. J. L. SCI. & TECH.

[Vol. 21:2

. . . [and] to synthetically create BRCA cDNA.”84 Because “isolation is necessary to conduct genetic testing,” Myriad’s patents
also gave it a monopoly over diagnostic applications of the
BRCA1 and BRCA2 genes.85 The case arose on an action for declaratory judgement seeking a declaration that Myriad’s patents
were directed to ineligible subject matter and therefore invalid
under 35 U.S.C. § 101.86
The Court found that Myriad’s claims to full-length gene sequences were invalid under 35 U.S.C. § 101 because they represent naturally occurring DNA sequences and that neither discovering the chromosomal location of a gene nor “separating the
gene from its surrounding genetic material . . . is an act of invention.”87 However, recognizing that naturally occurring genomic
DNA sequences contain subsections known as “introns” and “exons,” the Court ruled that claims for cDNA sequences were patent-eligible because those sequences contain only exons and
therefore represent a DNA sequence that is not naturally occurring.88 The Court further recognized that there may be a sequence of cDNA that is sufficiently short so that it has an identical sequence to a genomic DNA sequence, and that such a
cDNA would not be patent-eligible under 35 U.S.C. § 101.89 Importantly, the Court did not address method claims directed to
or involving DNA sequences,90 though it did suggest that the
techniques for isolating DNA described in Myriad’s patents were
“well understood, widely used, and fairly uniform,”91 suggesting
that they would likely be patent ineligible. Further, the Court
did not directly address the patent eligibility of a DNA molecule
having an unusual or non-natural composition, as Myriad’s

84. Id. at 585.
85. Id.
86. Id. at 589 n.3.
87. Id. at 592.
88. Id. at 594–95 (“cDNA retains the naturally occurring exons of DNA, but
it is distinct from the DNA from which it was derived. As a result, cDNA is not
a ‘product of nature’ and is patent eligible under § 101 . . . .”).
89. Id. at 595 (“[A cDNA sequence is patent eligible] except insofar as very
short series of DNA may have no intervening introns to remove when creating
cDNA.”).
90. Id. (“[T]here are no method claims before this Court.”).
91. Id. at 595–96 (internal quotation marks omitted) (quoting Ass’n for Molecular Pathology v. U.S. Pat. & Trademark Office, 702 F. Supp. 2d 181, 202–
03 (S.D.N.Y. 2010)).

2020]

SILENCING INNOVATION

345

claims were primarily directed to nucleotide sequences rather
than chemical compositions.92
In University of Utah Research Foundation v. Ambry Genetics, a case related to Myriad Genetics, Myriad filed suit against
Ambry Genetics for infringing three of its patents, including two
of the patents at issue in Myriad.93 Myriad alleged that Ambry
sold kits to detect susceptibility to certain breast and ovarian
cancers—Ambry counterclaimed that the relevant patents were
invalid under 35 U.S.C. § 101.94 Specifically, Ambry alleged that
four composition of matter claims directed to DNA primers
(“short, synthetic, single-stranded DNA molecules” that are complementary to a specific nucleotide sequence95 and are capable
of initiating DNA replication)96 and two method claims “involv[ing] comparisons between the wild-type BRCA sequences
with the patient’s BRCA sequences” were invalid.97
Citing Myriad’s proposition that claims to DNA sequences—
including those that do not occur naturally, like the synthetic
DNA primers claimed in Myriad’s patents—as short as 15 nucleotides (the length of the primers in Myriad’s claims) could be
held invalid if they have identical sequences to DNA molecules
found in nature, the Federal Circuit held Myriad’s claims to
DNA primers invalid under 35 U.S.C. § 101. Despite the fact that
the primers themselves were not naturally occurring and, in
fact, no DNA molecule having a single-stranded structure naturally occurs within the human body, the Court held the claims
invalid because they had an identical sequence to a portion of
naturally occurring DNA98 and therefore did not have a “unique
structure.”99 Moreover, the Federal Circuit found the fact that
92. Id. at 593 (“[Myriad’s] claim is concerned primarily with the information contained in the genetic sequence, not with the specific chemical composition of a particular molecule.”).
93. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 755, 757
(Fed. Cir. 2014). Ambry Genetics was decided by the Federal Circuit one year
after the Supreme Court’s ruling in Myriad.
94. Id. at 758.
95. Id. (internal quotation marks omitted) (citation omitted).
96. Primers, NATURE EDUC.: SCITABLE, https://www.nature.com/scitable/definition/primer-305 (last visited Nov. 12, 2018).
97. Ambry, 774 F.3d at 759.
98. Id. at 760.
99. Id. at 761 (emphasis added). The Federal Circuit’s holding is unclear as
to whether a nucleotide sequence is generally its “structure” for the purposes of
35 U.S.C. § 101 analysis or whether that is the case only for DNA primers. See
discussion infra Section III.B. (“[T]he Federal Circuit has used a nebulous, and
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DNA primers are able to serve as a starting material for DNA
polymerization irrelevant, holding that the primers did not “perform a significantly new function”100 despite the fact that naturally occurring DNA replication utilizes RNA primers rather
than DNA primers.101 Instead, the Federal Circuit identified the
function of DNA primers as the ability of “complementary nucleotide sequences [to] bind to each other,” which is an “innate ability of DNA.”102 Further, because the two method claims at issue
involved “comparison steps,” the Federal Circuit found that the
claims recited abstract ideas and subjected them to analysis under Alice.103 Under the second step of Alice, the Court found that
the “non-patent-ineligible elements” of the claims were “well-understood, routine, and conventional,” and therefore did not
“make the claims as a whole patent-eligible.”104
E. A RECENT CASE ELABORATES ON NUCLEOTIDE PATENT
ELIGIBILITY
A recent Federal Circuit case, Roche Molecular Systems, Inc.
v. CEPHEID, offers additional guidance on the patent eligibility
of nucleotide sequences.105 Primarily at issue in Roche were two
families of claims in a patent related to the detection rpoB, a
gene associated with drug-resistant strains of the pathogen Mycobacterium tuberculosis.106 The first claim family was directed
to a primer for use with polymerase chain reaction (PCR) tech-

perhaps counter-intuitive, definition of ‘nucleotide structure.’”); cf. Ambry, 774
F.3d at 761 (“Primers do not have [a unique] structure and are patent ineligible.”).
100. Ambry, 774 F.3d at 761.
101. See Appellants’ Opening Brief at 7, Ambry, 774 F.3d 755 (2014) (Nos.
14-1361, 14-1366) (“There are no short, single strands of DNA with a free 3′-OH
group in nature that can serve as primers. In natural DNA replication, RNA
primers are used as the starting material.”).
102. Ambry, 774 F.3d at 761.
103. Id. at 764.
104. Id.
105. Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1366 (Fed. Cir.
2018) (“[T]he [patent at issue] involves subjecting DNA extracted from a biological sample taken from a patient (e.g., a tissue or fluid sample) to amplification
by polymerase chain reaction (‘PCR’) using a short, single-stranded nucleotide
sequence (a ‘primer’).”).
106. See id. (“The [patent at issue] provides two types of claims: (1) composition-of-matter claims [of which there is one independent claim] . . . and (2)
process claims for methods [of which there is one independent claim] . . . .”).
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niques capable of “hybridizing” to rpoB and having “14–50 nucleotides.”107 The second claim family was directed to a process
for “amplifying” rpoB using a “plurality of primers” capable of
hybridizing to a “site comprising at least one position-specific
[M. tuberculosis] signature nucleotide” and “detecting” the amplified gene product.108
In a panel decision, a two-judge majority held that Ambry
dictated that the primers were patent ineligible because they
contained an identical sequence to naturally occurring DNA.109
The majority opinion rejected Roche’s arguments that the primers were chemically and structurally distinct from any naturally occurring DNA molecule, relying on the Ambry court’s rejection of similar arguments.110 Roche further argued that the
structure of its primers was more distinct from their relevant M.
tuberculosis DNA counterparts than was the case with the primer/gene pairs at issue in Ambry because M. tuberculosis has a
circular chromosome that lacks the 3’ end present in the primer
sequences. The majority opinion also rejected this argument, 111
as well as Roche’s contentions about the “specificity” of the primers described in the patent.112 Therefore, the majority found
that Roche’s primer claims were patent ineligible.113
As to the method claims at issue, the majority found that
the claims were directed to “a relationship between the . . . naturally occurring position-specific signature nucleotides and the
presence of [M. tuberculosis] in a sample.”114 Applying Alice, the
majority looked to the rest of the claim to see if there was an
“inventive concept that transforms [the claim] into patent-eligible subject matter.”115 It found that the “amplification” step was

107. Id. at 1367 (citing U.S. Patent No. 5,643,723 col. 28 ll. 14–31 (filed May
26, 1994)).
108. Id. (citing U.S. Patent No. 5,643,723 col. 25 l. 57–col. 27 l. 6 (filed May
26, 1994)).
109. Id. at 1371 (“[Roche’s primers] are indistinguishable from their corresponding nucleotide sequences on the naturally occurring DNA, and . . . therefore, are patent-ineligible within the meaning of § 101.”).
110. Id. at 1369–70 (citing Ambry, 774 F.3d at 761).
111. Id. at 1370.
112. Id.
113. Id. at 1371.
114. Id.
115. Id. at 1372.
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“‘routine’ when the patent application was filed”116 and that the
“detecting” step was “devoid of an inventive concept because it
involves a simple mental determination.”117 The majority further distinguished Roche’s method from a method for treating a
disease with a new drug because Roche’s claims relied on the
ability of their primers to hybridize to complementary nucleotide
sequences.118 The opinion classified the hybridization of complementary nucleotides as a patent-ineligible “law of nature.” 119
However, the majority stated in a footnote that they “express[ed]
no opinion on the subject matter eligibility of method claims that
exploit DNA or RNA for drug-like new applications.”120
Writing separately in a concurring opinion, Judge O’Malley
agreed that Ambry required that the claim be held invalid, but
felt that the court should “revisit [the] holding in [Ambry] at
least with respect to the primer claims.”121 O’Malley argued that
the validity of claims directed to DNA primer was not the question at issue in Ambry—rather, she characterized the question
before the Ambry court as whether the district court had abused
its discretion in denying a preliminary injunction.122 Moreover,
she suggested that the Federal Circuit’s decision in Ambry suffered from a lack of record evidence and that Roche’s DNA primer may have a unique, non-naturally occurring structure, and
further “challenge[d] the conclusion that th[e] entire class of
[DNA primer] molecules is ineligible under § 101.”123 O’Malley
distinguished the structure of DNA primers from their nucleotide sequence and therefore challenged the court’s determination of nucleotide structure based on only nucleotide sequence.124
Further, O’Malley found unclear how primers “are structurally

116. Id. (quoting Roche Molecular Sys., Inc. v. CEPHEID, No.14-CV-03228EDL, 2017 WL 6311568, at *15 (N.D. Cal. 2017)).
117. Id.
118. Id. at 1373.
119. Id.
120. Id. at 1373 n.6.
121. Id. at 1375 (O’Malley, J., concurring).
122. Id. (O’Malley, J., concurring).
123. Id. at 1377 (O’Malley, J., concurring).
124. Id. (O’Malley, J., concurring) (“[A] finding that the two [primers] have
identical sequences does not entirely resolve the question of whether they
are structurally identical because structure is not defined solely by nucleotide
sequence.”).
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identical to the ends of DNA strands found in nature.”125 Likewise, O’Malley found that the record before the court also suggested that the primers at issue have a unique function as compared to naturally occurring DNA.126 Ultimately, she found that
Roche had submitted “evidence . . . that, at the very least, raises
genuine issues of material fact as to whether there exists anything in nature that both has the structure and performs the
function of the claimed primers.”127
F. THERE ARE NO EXISTING INTERPRETATIONS OF § 101 AS
APPLIED TO SIRNA
There are virtually no adjudications of the patent eligibility
of claims directed to siRNA technologies.128 As discussed in Section I.E. of this note,129 the Federal Circuit has expressly declined to comment on the patent eligibility of claims directed to
RNA therapeutics.130 The Patent Trial and Appeal Board
(PTAB) found in Ex parte Khvorova that “the ability of siRNA
sequences to silence genes is ‘directed to naturally occurring phenomena.’”131 However, the patent at issue in Khvorova was specifically directed to an algorithm for “determining . . . whether a
particular siRNA sequence will result in gene silencing.”132 To
that extent, the PTAB did not decide on the patent eligibility of
RNA therapeutics. The PTAB ultimately found that the claim at
issue “does not recite a specific algorithm . . . [and] preempts any
algorithm for designing siRNA sequences,” and therefore was
patent ineligible under 35 U.S.C. § 101.133

125. Id. (O’Malley, J., concurring) (quoting Ambry, 774 F.3d at 760) (internal
quotation marks omitted).
126. Id. at 1380 (O’Malley, J., concurring).
127. Id. at 1381 (O’Malley, J., concurring).
128. See Esmond & Chung, supra note 12, at 26–27 (describing litigation of
siRNA as dealing with inventorship, patent malpractice, and trade secret disputes).
129. See discussion supra Section I.E.
130. Roche Molecular Sys., 905 F.3d at 1373 n.6.
131. Ex parte Khvorova, No. 2012-010359, 2015 WL 4267897, at *4 (P.T.A.B.
July 10, 2015) (quoting Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d
1371, 1376 (Fed. Cir. 2015)).
132. Id. at *3 (citing U.S. Pub. No. 10/940,892, claim 85 (filed Nov. 17, 2005)).
133. Id. at *5.
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G. THE PATENT LANDSCAPE OF SIRNA TECHNOLOGIES
A search of the Patent Full-Text Database for claims that
contain the term “siRNA” returns over 2,200 patents.134 Further,
a survey of siRNA patent families by Robert W. Esmond and
Alex Kwan-Ho Chung identified three main patent families of
siRNA technologies: the “Carnegie” patents, broadly directed to
double-stranded RNA (dsRNA) inhibition, the “Tuschl I” patents, directed to short (twenty-one to twenty-three nucleotide)
dsRNAs and methods of inhibition using short dsRNAs, and the
“Tuschl II” patents, claiming dsRNAs with nineteen to twentyfive nucleotides and 3’ overhangs as well as a method of preparing such dsRNAs.135 The Carnegie patents expired at the end of
2018, and therefore are not likely to prevent “generic” manufacture of siRNA therapeutics.136 However, both the Tuschl patent
families are set to expire in 2021, and therefore have the potential to “block companies from marketing [their own] siRNA therapeutics.”137 Esmond and Chung postulate that infringement litigation or inter partes review (IPR) may occur with regard to
these patents if a claimed siRNA therapeutic receives FDA approval prior to the expiry of their patent term.138 However, if no
therapeutic receives FDA approval by that time, any litigation
or IPR will likely concern a patent having a more specific claim
scope.139 As of September 15, 2017, there were 20 clinical trials
of miRNA- and siRNA-based therapeutics.140 More recently, the
FDA has for the first time granted marketing approval to an
siRNA-based therapy,141 indicating that there may soon be litigation concerning these foundational siRNA patents.142 RNA134. Patent Full-Text Database, U.S. PAT. TRADEMARK OFF.,
http://patft.uspto.gov/ (last visited Nov. 19, 2018) (follow “Advanced Search” hyperlink; then search for “ALCM/siRNA”).
135. Esmond & Chung, supra note 12, at 17–18.
136. Id. at 18.
137. Id.
138. See id. at 27 (describing the likelihood of litigation as compared to IPR
of a patented technology that achieves FDA approval prior to the expiry of its
relevant patent term).
139. Cf. id. (“After 2021, litigation concerning [the Carnegie, Tuschl I, and
Tuschl II] siRNA and nanoparticle patents will be unlikely, as no company will
have a dominating position.”).
140. Chakraborty et al., supra note 4, at 132.
141. RNA-Based Therapy, supra note 4.
142. But Cf. Esmond & Chung, supra note 12, at 27 (“After 2021, litigation
concerning siRNA and nanoparticle patents will be unlikely, as no company will
have a dominating position.”).
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based therapeutics more generally are expected to have significant economic growth within the next decade and at least one
organization has suggested that RNAi technologies could represent a $1.81 billion market by 2025.143
H. PATENT PROTECTION ENCOURAGES INVESTMENT
Because of the high cost of both developing and performing
clinical trials on a new drug, “pharmaceutical companies are
rarely willing to develop drugs without patent protection.”144 A
developer of a new drug may spend “hundreds of millions of dollars on clinical trials” while the drugs manufactured by a generic
competitor are “exempted from [safety and efficacy standards]
and enter the market at minimal cost[,]”145 making patent protection arguably more important to pharmaceutical developers
than other industries.146 To this end, pharmaceutical manufacturers “regularly screen their drugs in R&D and discard ones
with weak patent protection.”147 Like conventional therapeutics,
siRNA-based drugs also require FDA approval,148 and will therefore encounter similar financial hurdles as conventional therapeutics. Some commentators have expressed fears that recent
interpretations of 35 U.S.C. § 101 (including Mayo and Myriad)
could “curtail further research and investment in areas broader”
than the subject matter covered by the judicial exceptions.149
Though at least one decision from the Federal Circuit seems to
have utilized economic investment as justification that a tech-

143. See Antisense & RNAi Therapeutics Market Size Worth $1.81 Billion By
2025, GRAND VIEW RESEARCH (Mar. 2018), https://www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market [hereinafter Antisense & RNAi].
144. Benjamin N. Roin, Unpatentable Drugs and the Standards of Patentability, 87 TEX. L. REV. 503, 505 (2009).
145. Id.
146. Cf. id. (“At a time when many scholars believe that patents often do
more harm than good, the pharmaceutical industry is widely thought to showcase the benefits of patents.”).
147. Id.
148. See RNA-Based Therapy, supra note 4 (announcing the first FDA-approved siRNA-based drug).
149. See, e.g., Robert L. Stoll, Are Patent Decisions Strangling Our Economy?, HILL (May 13, 2016, 11:30 AM), https://thehill.com/blogs/punditsblog/technology/279830-are-patent-decisions-strangling-our-economy
(“This
spate of decisions is clouding the validity of patents in everything from diagnostic methods to personalized medicine to business methods and gaming.”).
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nology is not “conventional, routine, and well-understood” at Alice step two,150 “labor” or “investment” in developing a technology is generally insufficient to overcome challenges under 35
U.S.C. § 101.151
II. ANALYSIS
The potential 35 U.S.C. § 101 eligibility of siRNA patent
claims will be discussed by applying Supreme Court and Federal
Circuit precedent on DNA patents. In particular, siRNA will be
analyzed because of its utility in medical applications.152 Since
the vast majority of siRNA patents are claimed as compositions
of matter or processes,153 each of these statutory classes will be
addressed separately. Moreover, the major patent families identified by Esmond and Chung will be utilized as relevant examples of siRNA claim formulation.154
A. SIRNA IS LIKELY INELIGIBLE AS A COMPOSITION OF MATTER
Claims to siRNA formulated as a composition of matter may
likely be patent-ineligible under the rulings in Myriad155 and

150. Cf. Exergen Corp. v. Kaz USA, Inc., 725 F. App’x 959, 966 (Fed. Cir.
2018) (“Following years and millions of dollars of testing and development, the
inventor determined for the first time the coefficient representing the relationship between temporal-arterial temperature and core body temperature and incorporated that discovery into an unconventional method of temperature measurement.”) (emphasis added).
151. See, e.g., Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569
U.S. 576, 577 (2013) (“[E]xtensive effort alone is insufficient to satisfy § 101’s
demands.”).
152. See Lam et al., supra note 45, at 255 (describing siRNAs as “extremely
useful for targeting single gene disorders” and as having been favored by researchers as potential therapeutics due to the uncertainty surrounding miRNA
“mechanism of action and specificity”).
153. See, e.g., U.S. Patent No. 8,552,171 (filed Oct. 10, 2004) (claiming siRNA
as a composition of matter); see, e.g., U.S. Patent No. 6,506,559 (filed Dec. 18,
1998) (claiming siRNA as a process). See generally Esmond & Chung, supra note
12, at 17–18 (detailing three fundamental families of siRNA patents as claiming
compositions of matter or processes).
154. See Esmond & Chung, supra note 12, at 17–18.
155. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576
(2013).
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Ambry.156 Generally, siRNAs function by complementary interaction with a target mRNA.157 In Myriad, the Court held that
cDNA was patent-eligible insofar as it does not contain intron
sequences that would otherwise be present in the corresponding
genomic DNA sequence.158 The Federal Circuit restated this
holding in Ambry as generally prohibiting composition of matter
claims directed to nucleotides sequences having a utility based
on complementary binding.159 Under the holding in Myriad, patents directed to siRNA molecules would likely not be patenteligible if they claimed sequences identical to a naturally occurring mRNA molecule.160 Patents that claim siRNA that is “perfectly complementary to an mRNA” 161 are likely to be found patent ineligible in view of Myriad because there are no “intron
sequences” to remove when designing siRNA molecules. Since
siRNA must have perfect identity with a target mRNA in order
to induce a silencing effect,162 this is likely to be problematic for
claims to siRNA as a composition of matter. Neither the therapeutic function of the siRNA163 nor the specificity of an siRNA to
any particular mRNA164 is likely to improve the patent eligibility
of a perfectly complementary siRNA sequence in view of Ambry’s

156. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775 (Fed.
Cir. 2014).
157. See Pratt & MacRae, supra note 3, at 17899 (“[T]he [miRNA or siRNA]
guide strand form[s] a Watson-Crick-paired, A-form double helix with a complementary region of the target RNA.”).
158. Myriad, 569 U.S. at 595.
159. Ambry, 774 F.3d at 761.
160. Cf. Myriad, 569 U.S. at 595 (“As a result, cDNA is not a ‘product of
nature’ and is patent eligible under § 101, except insofar as very short series of
DNA may have no intervening introns to remove when creating cDNA.”).
161. See, e.g., U.S. Patent No. 8,552,171 (filed Oct. 10, 2004) (claiming siRNA
that is “perfectly complementary to an mRNA.”).
162. See Lam et al., supra note 45, at 253 (“To elicit RNAi, the siRNA must
be fully complementary to its target mRNA.”).
163. See Ambry, 774 F.3d at 760–61 (holding that the primary function for
the purposes of patent eligibility of a complementary nucleotide is the ability of
one complementary nucleotide sequence to bind to another even where the nucleotide sequence performs other functions).
164. See Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1370 (Fed.
Cir. 2018) (holding that nucleotide sequences that are bind to natural sequences
with high specificity are patent ineligible if they have an identical sequence to
a naturally occurring sequence).
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prohibition on the patenting of nucleotides having a utility based
on complementary binding.165
However, many siRNA sequences contain additional nucleotides or other alterations that could be a “chemical modification” sufficient to render the sequence patent-eligible.166 For example, the Tuschl II family of patents claim siRNA therapeutics
that contain a 3’ overhang of one to three nucleotides.167 The
Federal Circuit has indicated that mutations can render otherwise ineligible sequences patent-eligible.168 Though the Federal
Circuit has not provided guidance as to how many mutations are
required for patent eligibility of such a sequence, its emphasis
on disallowing DNA having “identical nucleotide sequences as
naturally occurring DNA” suggests that even a single altered nucleotide may be sufficient to make a sequence patent-eligible. 169
Adding nucleotides should be treated by the courts as equivalent
to mutating nucleotides because either process makes the relevant nucleotide sequence “different from those found in nature.”170 Likewise, claims to siRNA that contain non-naturally
occurring nucleotides171 may be patent-eligible because naturally occurring sequences inherently do not contain non-naturally occurring nucleotides. However, would-be patentees cannot
simply add “conventional” 3’ nucleotide overhangs172 in order to
bring their claims into patent eligibility,173 likely limiting this
strategy of patent claiming to overhangs or modifications that
165. See Ambry, 774 F.3d at 761 (holding that the ability of DNA primers to
selectively bind a target DNA sequence is not a “significantly new function”).
166. See Roche Molecular Sys., 905 F.3d at 1370 (“[A] primer having an identical nucleotide sequence to naturally occurring DNA without further chemical
modification is a natural phenomenon.”).
167. See, e.g., U.S. Patent No. 8,362,231 (filed Mar. 24, 2011) (claiming an
RNA molecule wherein “at least one RNA strand forms a single-stranded 3’overhang from 1 to 3 nucleotides”).
168. See Roche Molecular Sys., 905 F.3d at 1369 (“Nothing in the ’723 patent
suggests that the Roche inventors introduced any mutations that would have
made the primers’ nucleotide sequences different from those found in nature.”).
169. See, e.g., id. at 1370 n.5 (“We do not address the subject matter eligibility of primers that have been altered.”).
170. Id. at 1369.
171. See, e.g., U.S. Patent No. 8,552,171 (filed Oct. 10, 2004).
172. See, e.g., Lam et al., supra note 45, at 255 (citing Walton et al., supra
note 57, at 4807) (describing conventional siRNA overhangs).
173. See Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66,
at 79 (2012) (holding that “well-understood, routine, conventional activity previously engaged in by scientists in the field” is not sufficient to bring patent
ineligible subject matter into § 101 eligibility).
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themselves are novel.174 Because the common overhangs of
siRNA are conventionally limited to a small pool of sequences,175
they are likely insufficient to improve the patent eligibility of
siRNA composition of matter claims.176
Further, any argument that claims to explicitly doublestranded siRNA should be patent-eligible for the reason that a
complementary mRNA is single-stranded as it exists in nature
is likely to be rejected. Because the Federal Circuit held in Ambry that “separating DNA from its surrounding genetic material
[is] not an act of invention,”177 the argument would draw
strength from the fact that the second strand of a doublestranded siRNA does not serve to “separate” it from its surrounding environment. Rather, the second strand can be described as “added” over the single-strand present in the complementary mRNA.178 However, because the Federal Circuit has
indicated that nucleotides deriving utility from complementary
binding are generally patent ineligible, an argument that an
RNA is patent-eligible by reason of a two-stranded, complementary structure is likely be to rejected (even if that structure does
not exist in nature) because complementarity is “[o]ne of the primary functions of [nucleotide] structure in nature.”179
B. SIRNA METHOD CLAIMS HAVE LIMITED PATENT ELIGIBILITY
Only the Federal Circuit has provided guidance on patent
eligibility of methods involving nucleotide sequences,180 doing so
in Ambry and Roche.181 However, Ambry dealt with method
174. Cf. id.
175. See, e.g., Lam et al., supra note 45, at 255 (citing Walton et al., supra
note 57, at 4807) (“A conventional siRNA consists of 19–21 nucleotides with two
nucleotide overhangs at the 3′ end, usually TT and UU, which are important for
recognition by the RNAi machinery.”).
176. Cf. Mayo, 566 U.S. at 79 (holding that “conventional activity previously
engaged in by scientists in the field” is insufficient to cure patent ineligibility).
177. Id. (citing Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569
U.S. 576, 591) (internal quotation marks omitted).
178. See, e.g., Lam et al., supra note 45, at 252.
179. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775, 761
(Fed. Cir. 2014).
180. Id. at 761 (citing Ass’n for Molecular Pathology v. Myriad Genetics, Inc.,
569 U.S. 576, 595) (“While we addressed some of the method claims of the ‘441
patent in our Myriad decision, the Supreme Court did not address any method
claims.”).
181. Id. at 764; Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1366
(Fed. Cir. 2018).
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claims directed to the detection of mutations following routine
DNA amplification or probe hybridization.182 Likewise, the
method claims contested in Roche were directed to a method of
detecting a gene product based on amplification by polymerase
chain reaction (PCR).183
Of the major siRNA patent families identified by Esmond
and Chung as examples, only U.S. 8,420,391 (the ‘391 patent) of
the Tuschl I claims a method for using siRNA sequences.184 The
‘391 patent recites a method for “introducing” siRNA into cells,
“maintaining” the resulting cells under conditions suitable for
RNA interference, and “thereby producing” a knockdown effect,
reducing the expression of a particular gene.185 Unlike the
claims contested in Ambry and Roche, these claims do not recite
the abstract idea of “comparing,”186 but nonetheless likely recite
a patent-ineligible natural phenomena. The steps recited by the
‘391 patent are similar to those recited by the patent at issue in
Mayo—that is, the knockdown effect recited by the ‘391 patent
is produced by interaction of the siRNA with the RNAi pathway,
which exists in nature.187 To that extent, “producing” a knockdown effect by using that natural phenomena is also patent-ineligible subject matter.188 Though there is no caselaw from article III courts on point, the PTAB has ruled consistently with this
analysis.189 The question then is whether the remainder of the

182. Ambry, 774 F.3d at 764.
183. Roche Molecular Sys., 905 F.3d at 1366.
184. See, e.g., U.S. Patent No. 8,420,391 (filed Nov. 24, 2011); see also Esmond & Chung, supra note 12, at 17–18.
185. U.S. Patent No. 8,420,391 (filed Nov. 24, 2011) (reciting four independent claims containing only “introducing,” “maintaining,” and “producing” steps).
186. Ambry, 774 F.3d at 764; Roche Molecular Sys., 905 F.3d at 1369.
187. Cf. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66,
77 (2012) (“Prometheus’ patents set forth laws of nature—namely, relationships
between concentrations of certain metabolites in the blood and the likelihood
that a dosage of a thiopurine drug will prove ineffective or cause harm.”). See
generally RNA Interference (RNAi), supra note 1.
188. Cf. Mayo, 566 U.S. at 77 (“If a law of nature is not patentable, then
neither is a process reciting a law of nature, unless that process has additional
features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself.”).
189. See ex parte Khvorova, No. 2012-010359, 2015 WL 4267897, at *4
(P.T.A.B. July 10, 2015) (quoting Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788
F.3d 1371, 1376 (Fed. Cir. 2015)).
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claims “add ‘enough’ to make the claims as a whole patent-eligible.”190 The other steps recited by the ‘391 patent are “introducing” and “maintaining.”191 It is likely that these steps do not add
enough to make the claims as a whole patent-eligible.
Looking to Ambry, “techniques that a scientist would have
thought of” are insufficient to cure patent-ineligible subject matter.192 Likewise, Mayo held that even a combination of steps is
ineligible where “the combination amounts to nothing significantly more than an instruction to [the relevant audience] to apply the applicable laws [of nature].”193 The ‘391 patent appears
to fail both formulations. Expert testimony notwithstanding, it
is obvious that a scientist would have thought of “introducing”
RNAi-capable RNA and “maintaining” cells in conditions suitable for RNAi in order to produce an RNAi-mediated knockdown.194 Likewise, these steps are effectively an instruction on
how to apply the law of nature, because producing an RNAi-mediated knockdown requires RNAi-capable RNA and “conditions
under which RNA . . . interference occurs.”195 Therefore, siRNA
patents should avoid the formulation used by the ‘391 patent in
order to avoid invalidity for failing to recite patent-eligible subject matter. Further, Ambry expressly forecloses the patenting
of a DNA sequence based on its ability to “hybridize,” meaning a
claiming strategy focused on the initial siRNA/mRNA hybridization event is just as likely to fail for failing to recite patent-eligible subject matter as claims focused on the later knockdown
event.196
Two patents from the Tuschl II family offer a different approach to siRNA method claims by reciting methods of producing
siRNA molecules.197 Both U.S. Patent No. 7,056,704 and U.S.
Patent No. 7,078,196 recite “synthesizing” two RNA strands and

190. Ambry, 774 F.3d at 764.
191. U.S. Patent No. 8,420,391 (filed Nov. 24, 2011).
192. Ambry, 774 F.3d at 764.
193. Mayo, 566 U.S. at 79.
194. Cf. Lam et al., supra note 45, at 255–56 (summarizing existing bestpractices for RNA interfering techniques).
195. Compare id., with U.S. Patent No. 8,420,391 (filed Nov. 24, 2011).
196. See Ambry, 774 F.3d at 761 (finding that the ability of DNA primers to
hybridize to other DNA strands is simply a manifestation of “the innate ability
of DNA to bind to itself”).
197. U.S. Patent No. 7,056,704 (filed Dec. 23, 2004); U.S. Patent No.
7,078,196 (filed Nov. 11, 2004); see Esmond & Chung, supra note 12, at 17–18.
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“combining” the synthesized strands.198 Insofar as the claims
cannot be construed to cover unpatentable siRNA sequences (as
discussed in section II.A of this note),199 this type of method
claim may be patent-eligible. However, because synthesizing
and combining are “routine” and “conventional,” this type of
claiming strategy likely does not function as a workaround to the
validity of a corresponding composition of matter claim, 200 and
may therefore have extremely limited practical utility to patent
drafters.
C. CLAIMING A METHOD OF TREATMENT REMAINS AN OPTION TO
OVERCOME § 101 HURDLES
Instead of patenting methods of administering siRNA to
trigger the RNAi biological pathway, would-be siRNA patentees
might be able to overcome § 101 challenges by following the patent held subject-matter eligible in Vanda and formulating their
claims as a method of treating a disease or disorder.201 Though
the treatment in that case utilized a small molecule, the court’s
holding did not rest on the small molecule’s structure, but rather
that the patent at issue recited “a novel method of treating a
disease.” 202 Further, the Vanda court distinguished the patent
eligibility of a natural law applied to “treating a disease” from
the same natural law applied to “administering a drug,” holding
that using a natural law to treat a disease is patent-eligible subject matter.203 Therefore, the Federal Circuit’s holding in Vanda
very likely opens up the door for the patenting of methods of
treating diseases with siRNA, even where the siRNA itself is

198. U.S. Patent No. 7,056,704 (filed Dec. 23, 2004); U.S. Patent No.
7,078,196 (filed Nov. 11, 2004).
199. See discussion of the patentability of siRNA as a composition of matter
supra Section II.A.
200. See Ambry, 774 F.3d at 760 (“[A]s the district court in the earlier Myriad case and our opinion in Myriad made clear, isolated DNA is routinely synthetically created.”).
201. Cf. Vanda Pharm., Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 1117,
1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (Jan. 17, 2019)
(No. 18-817) (holding a method of treating schizophrenia to be patent-eligible
subject matter).
202. Id. at 1134.
203. Id. (citing Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566
U.S. 66, 74 (2012)) (“Although the representative claim in Mayo recited administering a thiopurine drug to a patient, the claim as a whole was not directed to
the application of a drug to treat a particular disease.”).
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otherwise patent ineligible.204 However, the court’s holding
seems to indicate that such a method claim would need to identify both “specific doses” and a “specific disease” to be treated, 205
which may pose a challenge for siRNA researchers trying to patent their technology without performing clinical studies. A petition for certiorari has been filed but has not yet been granted,
potentially subjecting this approach to an opportunity for reversal by the Supreme Court.206
III. ALTERNATIVE INTERPRETATIONS AND
LEGISLATIVE SOLUTIONS
A lack of patent protection could seriously impact future development of siRNA therapeutics, which are forecasted to have
significant market growth in the next few years.207 Part III of
this note will explore alternative interpretations of 35 U.S.C. §
101 that may confer patent eligibility onto siRNA therapeutics
as well as the role that sections of the Patent Act outside of § 101
can have to constrain overly broad nucleotide patents under a
more open interpretation of 35 U.S.C. § 101. Further, it will explore legislative solutions to incentivize siRNA therapeutic development through non-patent market protections.
A. A LACK OF PATENT PROTECTION MAY STIFLE DEVELOPMENT
OF SIRNA THERAPEUTICS
Because pharmaceutical firms tend to discard conventional
drugs with “weak patent protection” during the drug development process,208 limiting the range of patents available to siRNA
therapeutics could significantly impact their development by
private research organizations. Private research investment is
likely critical to rapid development and deployment of any therapeutic compound as pharmaceutical firms currently carry out

204. Cf. id. at 1135 (holding that “treating a disease” is a patent eligible application of a natural law).
205. See id. at 1136 (“[T]he [patent-eligible] claims here are directed to a
specific method of treatment for specific patients using a specific compound at
specific doses to achieve a specific outcome.”).
206. See generally id.
207. See, e.g., Antisense & RNAi, supra note 143.
208. See Roin, supra note 144, at 505.
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the majority of drug development in the United States.209 As contrasted with the diagnostic methods found ineligible in Mayo
and Roche,210 the development of therapeutic products benefit
from exclusive licensing.211 Unless an interpretation of Ambry
that is favorable to siRNA patenting is adopted by the courts 212
or a legislative solution ensuring siRNA therapeutic market exclusivity is adopted by Congress,213 it is likely that the primary
route to patent protection for these compounds exists using the
limited “method of treatment” approach as outlined in Section
II.C.214
Federal Circuit precedent states that infringement of a
method patent can occur only where a single party performs all
steps of the claimed method.215 Thus, only a physician administering the siRNA could be liable for direct infringement of claims
directed to a method of treatment using siRNA.216 Generally,
physician liability is severely limited by 35 U.S.C. § 287(c),

209. See generally Henry G. Grabowski et al., The Roles of Patents and Research and Development Incentives in Biopharmaceutical Innovation, 34
HEALTH AFF. 302, 303 (describing the role of patents in biopharmaceutical innovation as “essential”); cf. Ashley J. Stevens et al., The Role of Public-Sector
Research in the Discovery of Drugs and Vaccines, 364 NEW ENG. J. MED. 535,
539–40 (2011) (finding that only 13.6%–21.1% of new drug applications originated from public sector research institutes).
210. Mayo Collaborative Servs. v. Prometheus Labs. Inc., 566 U.S. 66, 87–
88 (2012) (finding a diagnostic test based on a metabolite level to be a patentineligible law of nature); Roche Molecular Sys. Inc. v. CEPHEID, 905 F.3d 1363,
1370–71 (Fed. Cir. 2018) (finding a method of diagnosis using DNA amplification and associated DNA primers to both be patent ineligible).
211. Cf. Julia Carbone et al., DNA Patents and Diagnostics: Not a Pretty Picture, 28 NATURE BIOTECH. 784, 785 (2011) (“[T]here is no evidence to suggest
that exclusive licensing is as important in the field of diagnostic testing as in
therapeutics in creating products that would not otherwise exist.”) (emphasis
added).
212. See, e.g., discussion infra Section III.C.
213. See, e.g., discussion infra Section III.E.
214. See discussion of method of treatment patents supra Section II.C.
215. Limelight Networks, Inc. v. Akamai Techs., Inc., 572 U.S. 915, 919
(2014) (citing Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318, 1329 (Fed.
Cir. 2008)).
216. Cf. id. at 921–22 (“The Federal Circuit held in Muniauction that a
method’s steps have not all been performed as claimed by the patent unless they
are all attributable to the same defendant, either because the defendant actually performed those steps or because he directed or controlled others who performed them.”).
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which gives immunity for violations of some medical activity patents to licensed medical practitioners,217 though §
287(c)(2)(A)(iii) specifically limits this immunity to allow liability for “the practice of a process in violation of a biotechnology
patent.”218 There is no statutory definition of what constitutes a
“biotechnology patent,” but the section’s legislative history indicates that the provision likely would allow a physician to be liable for infringement of an siRNA-based patented method of
treatment.219 However, patentees may be reluctant to sue physicians given that lawsuits against doctors for infringing method
of treatment patents have historically prompted extremely negative reactions from the public.220 At least to this extent, patentees may likely prefer to sue generic manufacturers for indirect
infringement under §§ 271(b)–(c) rather than for direct infringement under § 271(a).221
Liability under § 271(b) requires actual knowledge of the infringed patent.222 Moreover, under § 271(b), the patentee has the
burden of proving that the alleged infringer “possessed specific
intent to encourage another’s infringement.”223 The specific intent for inducement liability “require[s] more than just intent to
cause the acts that produce direct infringement.”224 Likewise,

217. See 35 U.S.C. § 287(c) (1999).
218. 35 U.S.C. § 287(c)(2)(A)(iii) (2011).
219. Cf. H.R. REP. NO. 104-863, at 854 (1996) (Conf. Rep.) (“For the purposes
of [§ 287(c)(2)(iii)], the definition of the term ‘biotechnology patent’ includes a
patent on a ‘biotechnological process’ as defined in 35 U.S.C. § 103(b), as well as
a patent on a process of making or using biological materials, including treatment using those materials, where those materials have been manipulated ex
vivo at the cellular or molecular level.”).
220. See Sally Squires, AMA Condemns Patents for Medical Procedures,
WASH. POST (June 20, 1995), https://www.washingtonpost.com/archive/politics/1995/06/20/ama-condemns-patents-for-medical-procedures/b339653c-e4fa4991-ad41-e762edc52b16/; see also Katherine J. Strandburg, Legal but Unacceptable: Pallin v. Singer and Physician Patenting Norms 1, 16 (NYU Ctr. for
L., Econ. & Org., Working Paper No. 14-42, 2014) (describing the passage of §
287(c) as in response to Pallin v. Singer, a well-publicized suit concerning the
violation of a medical procedure patent).
221. See generally 35 U.S.C. § 271.
222. Glob.-Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754, 765–66 (2011).
223. DSU Med. Corp. v. JMS Co., 471 F.3d 1293, 1304 (Fed. Cir. 2006) (citing
Manville Sales Corp. v. Paramount Sys., Inc., 917 F.2d 544, 553 (Fed. Cir.
1990)).
224. Id. at 1306.
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deliberate indifference cannot prompt liability for indirect infringement.225 Reasonable belief of non-infringement has also
defeated inducement liability.226 The Federal Circuit has limited
inducement liability for the prescription of a generic compound
for infringing off-label uses.227 The District Court for the District
of Delaware has expanded on the intent requirement specifically
in regard to a “method of treatment” patent, holding that inducement liability can be avoided if a generic manufacturer does not
list the infringing use on the label of the drug.228 The court further held that even where the relevant generic label indicated
that it could be used to treat a disease identified in a patented
method of treatment, inducement liability cannot be found
where the direct infringer did not read the label.229 Because of
these hurdles, § 271(b) may not present a realistic opportunity
for siRNA patentees to collect damages from generic manufacturers of the compounds used in patented methods of treatment.
However, there is a possibility that an siRNA patentee could
successfully sue a generic manufacturer for contributory infringement under § 271(c). Like § 271(b), liability under § 271(c)

225. See Glob.-Tech Appliances, Inc., 563 U.S. at 770 (“[I]n demanding only
‘deliberate indifference’ to that risk, the Federal Circuit’s test does not require
active efforts by an inducer to avoid knowing about the infringing nature of the
activities.”).
226. Ecolab, Inc. v. FMC Corp., 569 F.3d 1335, 1351 (Fed. Cir.), amended on
reh’g in part, 366 F. App’x 154 (Fed. Cir. 2009) (holding that a jury could permissibly conclude that the defendant “reasonably believed” they were not infringing the patent at issue).
227. Takeda Pharm. U.S.A., Inc. v. W.-Ward Pharm. Corp., 785 F.3d 625,
633 (Fed. Cir. 2015) (holding that “speculation or even proof that some, or even
many, doctors would prescribe” a generic drug in a way that infringes a method
of treatment patent is likely insufficient for § 271(b) liability).
228. GlaxoSmithKline LLC v. Teva Pharm. USA, Inc., 313 F. Supp. 3d 582,
592 (D. Del. 2018) (holding that there cannot be inducement liability for selling
a drug used to infringe a method of treatment, because the generic’s “label omitted from its label the language contained on [the non-generic’s] label concerning
the use” of the drug to perform the patented method of treatment); see also
Takeda Pharm. U.S.A., Inc., 785 F.3d at 633.
229. See GlaxoSmithKline LLC, 313 F. Supp. 3d at 591 (“As Dr. McCullough
concedes that he did not read Teva’s label, he cannot state, for instance, that he
noticed or otherwise knew what (if anything) that label said about using carvedilol to treat CHF.”); but see AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042,
1060 (Fed. Cir. 2010) (holding that a generic label that provides specific treatment instructions, such as how many times a day to use the relevant drug or
what type of doses to utilize, may be sufficient evidence of intent for inducement
liability).
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requires actual knowledge of the infringed patent.230 The patentee’s burden of proof for liability under § 271(c) includes
showing that “the accused products are not staple articles of
commerce suitable for no substantial non-infringing uses.”231
Presumably, an siRNA used in a patented method of treatment
would not be a “staple article of commerce” and would have no
real use outside of the patented method due to the specificity of
siRNA-mediated gene silencing.232 Though contributory infringement is generally not recommended as a primary method
of patent enforcement,233 this remains a potential avenue of recovery against a generic manufacturer.
In short, siRNA therapeutics are likely restricted to a class
of patents enforceable for direct infringement only against physicians, with any theory of liability for generic manufacturers instead relying on contributory infringement. Because pharmaceutical companies value strong patent protection when
determining which products to develop,234 the limited enforcement strategies available to patentees could discourage the development of novel siRNA therapeutics.
B. THE FEDERAL CIRCUIT’S STANDARD MAY BE A SOURCE OF
CONFUSION
Compounding the aforementioned problems facing siRNA
patentees (as well as nucleotide patentees more generally), the
Federal Circuit has used a nebulous, and perhaps counter-intuitive, definition of “nucleotide structure.” Ambry rejected DNA
primers in spite of evidence that primers are single-stranded
and “single-stranded DNA cannot be found in the human
230. Glob.-Tech Appliances, Inc., 563 U.S. at 764 (citing Aro Mfg. Co. v. Convertible Top Replacement Co., 377 U.S. 476, 488 (1964)).
231. See, e.g., In re Bill of Lading Transmission & Processing Sys. Patent
Litig., 681 F.3d 1323, 1331 (Fed. Cir. 2012).
232. Cf. Golden Blount, Inc. v. Robert H. Peterson Co., 438 F.3d 1354, 1363
(Fed. Cir. 2006) (finding contributory infringement for sale of a fireplace burner
that was not a “staple article of commerce and was especially made” for use with
the plaintiff’s patented invention); see Lam et al., supra note 45, at 255 (describing siRNAs as “extremely useful for targeting single gene disorders”).
233. Cf. James Yang, Claim Drafting Tip: Focus on Direct, Not Indirect Infringement, OC PATENT L. (Sept. 14, 2015), https://ocpatentlawyer.com/claimdrafting-tip-focus-on-direct-not-indirect-infringement/ (discouraging the use of
claims that only capture indirect infringement).
234. See Roin, supra note 144, at 514 (“Moreover, it is well known that pharmaceutical companies generally refuse to develop new drugs unless they have
strong patent protection over them.”).
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body.”235 Ambry cites Myriad for the proposition that “separating
[DNA] from its surrounding genetic material is not an act of invention,” but does not explain how single-stranded primers are
analogous to isolating a gene.236 Further, Ambry held that primers do not have a “unique structure, different from anything
found in nature” potentially on that basis that the primers at
issue have an identical sequence to a gene found in nature.237
Likewise, the Federal Circuit in Roche rejected arguments
that Roche’s primers were structurally unique on the basis of 3’
hydroxyl groups that are not present in M. tuberculosis DNA.238
The court held that “distinction unavailing” and further that the
appropriate “subject matter inquiry of primer claims hinges on
comparing a claimed primer to its corresponding DNA segment
on the chromosome—not the whole chromosome,” citing a passage from Ambry “emphasizing the appropriate comparison being” that of nucleotide sequences.239 Ultimately, the Federal Circuit has left the meaning of “nucleotide structure” indeterminate
and uncertain.
Two potential working definitions of “nucleotide structure”
arise from a survey of Federal Circuit precedent. It is possible
that the Federal Circuit’s definition of “nucleotide structure” includes some, but not all, elements of nucleotide structure in the
patent eligibility analysis.240 If that is the case, the court has
failed to specifically enumerate which elements are useful to the
determination of patent eligibility, likely creating a recurring

235. Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775, 760
(Fed. Cir. 2014).
236. Id. at 759 (quoting Ass’n for Molecular Pathology v. Myriad Genetics,
Inc., 569 U.S. 576, 590 (2013)) (internal quotation marks omitted).
237. Cf. id. at 761 (citing Myriad Genetics, 569 U.S. at 589) (“A DNA structure with a function similar to that found in nature can only be patent eligible
as a composition of matter if it has a unique structure, different from anything
found in nature . . . [p]rimers do not have such a different structure and are
patent ineligible.”).
238. See Roche Molecular Sys., Inc. v. CEPHEID, 905 F.3d 1363, 1369–70
(Fed. Cir. 2018) (“Roche’s primers are indistinguishable from their corresponding nucleotide sequences on the naturally occurring MTB rpoB gene.”).
239. Id. at 1370 (citing Ambry, 774 F.3d at 760–61).
240. Cf., e.g., Ambry, 774 F.3d at 760 (“Myriad argues that primers are in
fact not naturally occurring because single-stranded DNA cannot be found in
the human body. But, as the Supreme Court made clear, ‘separating [DNA] from
its surrounding genetic material is not an act of invention.’”).
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source of uncertainty for patentees.241 Alternatively, it is possible that the Federal Circuit treats “nucleotide structure” as
meaning “nucleotide sequence.”242 This definition is divorced
from the conventional scientific understanding of DNA structure
as the molecular structure of a DNA molecule243 and seems particularly insensible in view of the Supreme Court’s scientificallynuanced handling of nucleotide patenting in Myriad.244 Hopefully, future holdings on the subject will clarify which definition
of “nucleotide structure” the Federal Circuit uses for patent eligibility analysis.
C. RE-THINKING AMBRY GENETICS
One way to bring siRNA therapeutics further into patent eligibility would be to revise the holding of Ambry, as has been
suggested by Judge O’Malley of the Federal Circuit.245 Specifically, Judge O’Malley has postulated that the Federal Circuit
erred in treating a nucleotide sequence as its structure for the
purposes of patent eligibility.246 Allowing unique chemical structures not found in nature, like the free 3’ hydroxyl groups of Ambry and Roche, to cure patent ineligibility of some nucleotide sequences may also carve out a space for the patenting of siRNA
as compositions of matter. As discussed in Part I of this note,
siRNA can have a number of structural features that are not

241. Cf., e.g., Roche Molecular Sys., 905 F.3d at 1370 (emphasizing that the
appropriate subject matter comparison for DNA primers is between the primers
and the naturally occurring sequence).
242. See id. at 1377 (O’Malley, J., concurring) (implying the majority conflated sequence with structure); cf., e.g., id. at 1371 (Fed. Cir. 2018) (“We hold
that the primers before us are indistinguishable from their corresponding nucleotide sequences on the naturally occurring DNA, and that the primer claims,
therefore, are patent-ineligible . . . .”).
243. See,
e.g.,
The
Structure
of
DNA,
BOISE
ST.
U.,
http://cs.boisestate.edu/~amit/teaching/342/lab/structure.html (last visited
Mar. 5, 2019) (describing the structure of DNA in terms of its molecular structure).
244. Cf. Myriad Genetics, 569 U.S. at 594–95 (distinguishing genomic DNA
from cDNA for the purposes of patent eligibility).
245. See Roche Molecular Sys., 905 F.3d at 1381 (O’Malley, J., concurring)
(“I believe, accordingly, that we should revisit our conclusion in BRCA1 en
banc.”).
246. See id. (“[A]s the record in this case reveals, a finding that the two [DNA
molecules] have identical sequences does not entirely resolve the question of
whether they are structurally identical because structure is not defined solely
by nucleotide sequence.”).
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present in naturally occurring mRNA sequences, such as being
double-stranded or having single-strand overhangs.247
D. THE REST OF THE PATENT ACT IS CAPABLE OF PREVENTING
OVERBROAD CLAIMS
In adopting restrictive interpretations of 35 U.S.C. § 101,
the courts have expressed a concern about the patenting of “basic
tools of scientific and technological work.”248 In fact, this principle was cited in both Myriad249 and Ambry.250 However, a number of alternatives exist within the Patent Act to prevent overbroad patents that extend to basic tools of scientific research. 35
U.S.C. § 112, for instance, acts to prevent “pure functional claiming” that can extend a patent’s scope to an idea or a basic research tool.251 Likewise, 35 U.S.C. § 102 incorporates the doctrine of “inherency” which “allows determination of whether
subject matter that is not taught in the single reference was
nonetheless known in the field of the invention.”252 Modern interpretations of the doctrine are able to broadly exclude claim
elements present in the prior art from patenting, including those
that may not have been recognized by persons of ordinary
247. See generally Lam et al., supra note 45, at 254 (comparing siRNA design
with miRNA design as a therapeutic gene agent).; see also discussion of siRNA
structure supra Section I.B
248. Gottschalk v. Benson, 409 U.S. 63, 67 (1972).
249. See Ass’n of Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576,
589 (2013) (quoting Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566
U.S. 66, 71 (2012)) (“We have long held that [§ 101] contains an important implicit exception: Laws of nature, natural phenomena, and abstract ideas are not
patentable. Rather, they are the basic tools of scientific and technological work
that lie beyond the domain of patent protection.”) (quotations and citations
omitted).
250. See Univ. of Utah Research Found. v. Ambry Genetics, 774 F.3d 775,
764 (Fed. Cir. 2014) (citing Myriad Genetics, 569 U.S.at 589) (“[I]t is antithetical
to the patent laws to allow these basic building blocks of scientific research to
be monopolized.”).
251. See, e.g., Aristocrat Techs. Australia Pty Ltd. v. Int’l Game Tech., 521
F.3d 1328, 1333 (Fed. Cir. 2008) (“The point of [§§ 112(a)–(b)] is to avoid pure
functional claiming.”); cf. Med. Instrumentation & Diagnostics Corp. v. Elekta
AB, 344 F.3d 1205, 1211 (Fed. Cir. 2003) (“If the specification is not clear as to
the structure that the patentee intends to correspond to the claimed function,
then the patentee has not paid that price but is rather attempting to claim in
functional terms unbounded by any reference to structure in the specification.”).
252. Schering Corp. v. Geneva Pharm., Inc., 348 F.3d 992, 995 (Fed. Cir.
2003) (“The analytic tool of ‘inherency’ allows determination of whether subject
matter that is not taught in the single reference was nonetheless known in the
field of the invention [and therefore anticipated].”).

2020]

SILENCING INNOVATION

367

skill.253 Further, some scholars have argued that the second step
of the Alice framework254 overlaps with the obviousness inquiry
under § 103,255 thereby implying that patents on “basic tools of
scientific and technological work” can be prevented through §
103 instead of § 101.256 Effectively, there are several alternatives
to § 101 within the Patent Act available to prevent the patenting
of basic tools of scientific and technological work under a more
“relaxed” interpretation of Ambry that would allow for siRNA to
be patent eligible as a composition of matter.
E. NON-PATENT SIRNA MARKET EXCLUSIVITY COULD
INCENTIVIZE INVESTMENT
In lieu of patent protection, Congress could extend an alternative form of limited market exclusivity to siRNA therapeutics.
In theory, such a grant of exclusivity could resemble the already
existing grant supplied to so-called “orphan drugs” (those that
treat rare diseases).257 Historically, pharmaceutical companies
have viewed orphan drugs as unprofitable and avoided investing
in their development.258 Congress successfully incentivized the
development of orphan drugs259 by conferring on them a seven-

253. In re Cruciferous Sprout Litig., 301 F.3d 1343, 1349 (Fed. Cir. 2002)
(quoting MEHL/Biophile Int’l Corp. v. Milgraum, 192 F.3d 1362, 1365 (Fed. Cir.
1999)) (“Inherency is not necessarily coterminous with the knowledge of those
of ordinary skill in the art. Artisans of ordinary skill may not recognize the inherent characteristics or functioning of the prior art.”) (internal quotation
marks omitted).
254. That is, whether the claim elements are “well-understood, routine, or
conventional.” Alice Corp. Pty. v. CLS Bank Int’l, 573 U.S. 208, 225 (2014) (quoting Mayo, 566 U.S. at 73) (internal quotation marks omitted).
255. See Paxton M. Lewis, The Conflation of Patent Eligibility and Obviousness: Alice’s Substitution of Section 103, 2017 UTAH ONLAW: THE UTAH L. REV.
ONLINE SUPPLEMENT 13, 14 (2017) (“[Step two of the Alice framework] already
takes place under section 103 for obviousness . . . .”).
256. Cf. id. at 27 (illustrating how some Federal Circuit judges have used
obviousness and patent eligibility interchangeably).
257. OFFICE OF INSPECTOR GEN., DEP’T OF HEALTH & HUMAN SERVS., OEI09-00-00380, THE ORPHAN DRUG ACT IMPLEMENTATION AND IMPACT (2001), at
1 (defining orphan drugs in the U.S. as those that treat “a disease that affects
fewer than 200,000 people”).
258. See id. at 4 (finding the drugs used to treat for small patient populations
unprofitable).
259. See id. at 7 (“The Orphan Drug Act’s incentives . . . motivate[s] companies to develop orphan products.”).
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year period of exclusive marketing rights.260 In the same way,
conferring a limited term of market exclusivity onto siRNA therapeutics could serve to incentivize their development in place of
patent rights.261 Congress has more recently passed the Biologics Price Competition Innovation Act (“BPCIA”), which grants a
twelve-year term of non-patent marketing exclusivity to certain
protein-based therapeutics.262 The text of the BPCIA does not
extend exclusivity to nucleotides, but given that the act does
grant exclusivity to other biomolecular therapeutics,263 legislation granting non-patent exclusivity to siRNA therapeutics
would likely be uncontroversial.264

260. See id. at 4 (providing three incentives including 7-year market exclusivity to sponsors of approved orphan products); see generally CTR. FOR DRUG
EVALUATION & RES., U.S. FOOD & DRUG ADMIN., PATENTS AND EXCLUSIVITY
(2015), at 2, https://www.fda.gov/downloads/drugs/developmentapprovalprocess/smallbusinessassistance/ucm447307.pdf (describing the statutory requirements for orphan drug exclusivity).
261. Cf. ORPHAN DRUG ACT IMPLEMENTATION AND IMPACT, supra note 257,
at 7 (describing the positive effect of market exclusivity on orphan drug development); cf. Angélique McCall & Gene Quinn, The FDA Process, Patents and
Market Exclusivity, IP WATCHDOG (Mar. 12, 2017), http://www.ipwatchdog.com/2017/03/12/fda-process-patents-market-exclusivity/id=79305/ (“A patent is not the only path to exclusivity. In fact, the FDA characterizes patents
and ‘exclusivity’ separately.”).
262. See 42 U.S.C. § 262(k)(7)(A)(2019); see also U.S. FOOD & DRUG. ADMIN.,
NEW AND REVISED DRAFT Q&AS ON
BIOSIMILAR DEVELOPMENT AND THE BPCI ACT (REVISION 2), at 12 [hereinafter
NEW AND REVISED DRAFT Q&AS] (describing the BPCIA as amending the definition of “biological product” at § 262(i) to include certain protein-based therapeutics).
263. See 42 U.S.C. § 262(i)(1); see also NEW AND REVISED DRAFT Q&AS, supra note 262, at 12 (interpreting “protein” as used in the BPCIA “to mean any
alpha amino acid polymer with a specific defined sequence that is greater than
40 amino acids in size”).
264. Because the BPCIA was passed as a component of the Patient Protection and Affordable Care Act, at least one commentator has expressed concern
about its continued viability in light of the recent Texas v. United States decision. See Kyle Faget, ACA Strike-Down: Salvaging the BPCIA via Severability,
FOLEY & LARDNER LLP: HEALTH CARE LAW TODAY (Jan. 2, 2019),
https://www.healthcarelawtoday.com/2019/01/02/aca-strike-down-salvagingthe-bpcia-via-severability/; see also Texas v. United States, 340 F. Supp. 3d 579,
614 (N.D. Tex. 2018) (finding the individual mandate of the Patient Protection
and Affordable Care Act unconstitutional in light of the Tax Cuts and Jobs Act
and further finding the individual mandate inseverable). To the extent that
Congress may have to create new legislation if they want to maintain a system
of limited market exclusivity for protein therapeutics, they would have an opportunity to include related protections for siRNA therapeutics. See id. at 614.
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CONCLUSION
This note has illustrated the problems of patent eligibility
that both would-be and current siRNA patentees may face. Like
traditional therapeutics, siRNA therapeutics have a costly research and development cycle, as well as a costly FDA-approval
process.265 Therefore, limiting the patent protection available to
siRNAs could seriously stifle their development.266 Further,
siRNA therapeutics could represent a $1.81 billion market by
2025,267 and have numerous advantages over conventional therapeutics,268 illustrating both the economic and medical needs to
encourage would-be patentees to invest in their development. In
fact, many diseases are likely to remain untreatable without
some kind of nucleotide-based therapy option.269
Under the dual holdings of Ambry and Myriad, it seems
likely that siRNA therapeutics will only be patent eligible as
methods of treatment, unless that option is foreclosed by potential Supreme Court review.270 As discussed in Part III of this
note,271 limiting the patent eligibility of siRNA therapeutics to
methods of treatment may limit enforcement options against generic manufacturers and thereby may discourage development
of siRNA therapeutics.272 This note has identified two options to
provide a form of market exclusivity to siRNA therapeutics in
order to incentivize their private development: adopting an alternative interpretation of Ambry that relaxes current § 101
standards to allow patenting of siRNA as compositions of matter,

265. See discussion of the FDA-approval process, pharmaceutical investment, and siRNA, supra Section I.H.
266. Roin, supra note 144, at 505 (“[P]harmaceutical companies are rarely
willing to develop drugs without patent protection.”).
267. Antisense & RNAi, supra note 143.
268. See, e.g., Bullis, supra note 52.
269. See, e.g., Novartis, supra note 15 (“[M]ost of the proteome is . . . undruggable.”).
270. See Vanda Pharm., Inc. v. W.-Ward Pharm. Int’l Ltd., 887 F.3d 1117,
1136 (Fed. Cir. 2018), petition for cert. filed, 87 U.S.LW. 3279 (U.S. Jan. 17,
2019) (No. 18-817).
271. See generally discussion of the role of effective market exclusivity in
driving investment in pharmaceutical-sector products supra Sections I.H, III.A,
and III.E.
272. Cf. Yang, supra note 233 (describing reasons for avoiding claims that
only capture indirect infringement).
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as discussed in Section III.C,273 and extending non-patent market exclusivity rights to siRNA therapeutics, as discussed in Section III.E.274

273. See discussion supra Section III.C.
274. See discussion supra Section III.E.

